Westover Capital Advisors LLC Purchases 3,332 Shares of Krystal Biotech, Inc. $KRYS

Westover Capital Advisors LLC acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,332 shares of the company’s stock, valued at approximately $1,108,000.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its position in Krystal Biotech by 27.3% during the third quarter. Signaturefd LLC now owns 168 shares of the company’s stock worth $56,000 after purchasing an additional 36 shares during the period. Torray Investment Partners LLC raised its position in shares of Krystal Biotech by 0.4% in the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after purchasing an additional 47 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of Krystal Biotech by 0.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock valued at $1,537,000 after purchasing an additional 53 shares during the period. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech during the 2nd quarter valued at approximately $30,000. Finally, HighTower Advisors LLC lifted its stake in shares of Krystal Biotech by 3.9% during the 2nd quarter. HighTower Advisors LLC now owns 2,129 shares of the company’s stock valued at $791,000 after buying an additional 80 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. This trade represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 13.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KRYS. Bank of America lifted their price objective on shares of Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Jefferies Financial Group restated a “buy” rating and set a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. HC Wainwright restated a “buy” rating and set a $361.00 target price on shares of Krystal Biotech in a research report on Thursday, October 15th. Weiss Ratings raised Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Finally, The Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They set a “buy” rating and a $441.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $377.20.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $313.66 on Tuesday. The company has a market capitalization of $9.28 billion, a price-to-earnings ratio of 39.31 and a beta of 0.50. The business has a 50 day moving average of $338.84 and a 200 day moving average of $307.01. Krystal Biotech, Inc. has a 1-year low of $183.26 and a 1-year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.33 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.